Enterprise Value
72.94M
Cash
42.86M
Avg Qtr Burn
-9.586M
Short % of Float
0.46%
Insider Ownership
3.51%
Institutional Own.
30.40%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tegoprubart (AT-1501) Details Renal Transplantation | Phase 2 Data readout | |
Tegoprubart (AT-1501) Details Type 1 diabetes, Islet Cell Transplantation | Phase 2 Data readout | |
Tegoprubart (AT-1501) Details Amyotrophic lateral sclerosis | Phase 2 Update | |
Tegoprubart (AT-1501) Details Autoimmune nephritis | Failed Discontinued | |
Tegoprubart (AT-1501) Details IgA nephropathy | Failed Discontinued |